Research overview
What is Semaglutide?
Semaglutide is a modified GLP-1 analogue with specific prescription injection and oral tablet products. Ozempic, Wegovy, and Rybelsus product claims and instructions are not interchangeable and do not automatically apply to research material.
What has research examined?
The randomized STEP 1 trial enrolled 1,961 adults with overweight or obesity without diabetes and found greater weight change with the studied once-weekly semaglutide product plus lifestyle intervention than placebo. FDA-submitted Wegovy labeling addresses approved indications, formulation, contraindications, and warnings. Supplier material is outside that evidence and quality system.
Clinical trial outcomes and prescription labels require controlled manufacturing and specified populations. No weight-loss treatment, amount, injection, or reconstitution advice is given.
Research references
- Once-weekly semaglutide in adults with overweight or obesity: STEP 1New England Journal of Medicine
- Wegovy semaglutide prescribing informationDailyMed; FDA-submitted labeling
Calculation boundary
Approved semaglutide products differ by formulation, route, concentration, and delivery device. A generic powder-vial/U-100 calculator cannot replace exact-product labeling or verify an unregulated supplier vial.